Insider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Buys $106,396.06 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) major shareholder Venrock Healthcare Capital Par bought 8,971 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were purchased at an average cost of $11.86 per share, with a total value of $106,396.06. Following the purchase, the insider now directly owns 4,044,684 shares of the company’s stock, valued at $47,969,952.24. The trade was a 0.22 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 14th, Venrock Healthcare Capital Par bought 88,794 shares of Oruka Therapeutics stock. The shares were purchased at an average cost of $11.44 per share, with a total value of $1,015,803.36.
• On Monday, February 10th, Venrock Healthcare Capital Par bought 574 shares of Oruka Therapeutics stock. The shares were purchased at an average cost of $10.90 per share, with a total value of $6,256.60.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $10.15 on Friday. The company has a market capitalization of $355.24 million, a P/E ratio of -1.62 and a beta of 0.77. Oruka Therapeutics, Inc. has a 52 week low of $9.53 and a 52 week high of $53.88. The firm’s 50 day moving average price is $14.29.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ORKA shares. Wedbush reissued an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Finally, Wolfe Research started coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price target for the company. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $39.86.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jefferies Financial Group Inc. bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $6,787,000. Toronto Dominion Bank bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $1,131,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Oruka Therapeutics by 22.2% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 583,327 shares of the company’s stock valued at $11,311,000 after acquiring an additional 106,000 shares in the last quarter. VR Adviser LLC increased its holdings in shares of Oruka Therapeutics by 6.5% during the fourth quarter. VR Adviser LLC now owns 3,285,620 shares of the company’s stock valued at $63,708,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $236,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.